INEOS¡ä BDO Plant Faces Shutdown in Germany
2025-10-28
Recently, INEOS announced on its official website that its BDO (1,4-butanediol) production plant in Marl, Germany, is facing a survival crisis.
According to Ineos, over 200 technical manufacturing jobs and the supply chain security of strategic products essential to Europe¡äs livelihood are at risk. It is reported that BDO serves as a key chemical intermediate in the production of antibiotics, antiretroviral drugs, statins, and vitamin B6, among other pharmaceuticals.
INEOS operates one of the cleanest and lowest-carbon BDO plants globally but has to bear the uniquely high carbon tax costs in Europe. If the government and the European Commission do not promptly block unfair imports, this production facility and its 200 jobs will face an uncertain future. Once domestic production capacity is lost, Europe will forfeit its critical independent drug manufacturing capability, leaving patients reliant on questionable and unstable overseas supply chains¡ªand even risking a dire shortage of life-saving medications.
Ineos CEO Andrew Brown stated: "While the U.S. aggressively supports its domestic industries, Europe suffocates its own sectors with high energy costs, carbon taxes, and suffocating bureaucracy. Without swift and robust trade barriers, Europe simply cannot compete with state-backed imports."
According to Ineos, over 200 technical manufacturing jobs and the supply chain security of strategic products essential to Europe¡äs livelihood are at risk. It is reported that BDO serves as a key chemical intermediate in the production of antibiotics, antiretroviral drugs, statins, and vitamin B6, among other pharmaceuticals.
INEOS operates one of the cleanest and lowest-carbon BDO plants globally but has to bear the uniquely high carbon tax costs in Europe. If the government and the European Commission do not promptly block unfair imports, this production facility and its 200 jobs will face an uncertain future. Once domestic production capacity is lost, Europe will forfeit its critical independent drug manufacturing capability, leaving patients reliant on questionable and unstable overseas supply chains¡ªand even risking a dire shortage of life-saving medications.
Ineos CEO Andrew Brown stated: "While the U.S. aggressively supports its domestic industries, Europe suffocates its own sectors with high energy costs, carbon taxes, and suffocating bureaucracy. Without swift and robust trade barriers, Europe simply cannot compete with state-backed imports."